Copyright © 2016

Aridis Pharmaceuticals, Inc.

5941 Optical Court, San Jose, CA 95138

Phone: 408-385-1742

Site Map

Privacy Policy

Financial Conflict of Interest Policy

Back to top

Previous page



Aridis Pharmaceuticals Strengthens Board of Directors with Former Wyeth (now Pfizer) President of R&D Robert Ruffolo, Jr..


Aridis Pharmaceuticals to Present at BIO CEO & Investor Conference 2016.


Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin® for Treating Hospital-Acquired and Ventilator-Associated Pneumonia.


Aridis Pharmaceuticals to Present at Biotech Showcase™ 2016.


Aridis Pharmaceuticals Receives Multiple NIH Grants.

Immunotherapy Using Monoclonal Antibodies is the Next Frontier in Fighting Infections
Featured Product

The biggest threat to global health today is antibiotic resistance. Aridis’ solution is to leverage the natural human immune system in the form of monoclonal antibodies to fight infections. This novel approach is also referred to as anti-infective immunotherapy.

We have developed a broad, unrivaled portfolio of anti-infective monoclonal antibodies or mAbs that target the infecting pathogens.  Aridis has three of the most advanced monoclonal antibodies that are in or about to enter phase 2 clinical testing to address the $30B antibiotic resistance market.

Our mAb therapies are complemented by a breakthrough discovery platform called MabIgX that  allows for  discovery of rare, protective antibody producing B-cells and the rapid transition to clinical testing.    

AR-301 (SalvecinTM) is a fully human monoclonal IgG1 antibody specifically targeting S. aureus alpha-toxin. Upon binding to its target antigen AR-301 represses functional toxin pore formation leading to protection of susceptible cells of the infected host from alpha-toxin dependent destruction. Its mode of action is independent of the antibiotic resistance profile of S. aureus, hence AR-301 is active against infections caused by both antibiotic resistant (MRSA) and antibiotic sensitive (MSSA) strains. Intravenous administration of AR-301 mAb to mice with acute pneumonia caused by S. aureus resulted in reduced bacterial loads and significantly improved survival rates. An international Phase 1/2a human clinical trial evaluating the safety and efficacy of AR-301 in hospital-acquired pneumonia (HAP) and ventilator- associated pneumonia (VAP) patients is nearing completion, with data expected in the second half of 2016.

More >>

More >>


Breakthrough Therapies for

Antibiotic Resistant Infections